Concepedia

Publication | Open Access

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

6.6K

Citations

29

References

2014

Year

Abstract

LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure. (Funded by Novartis; PARADIGM-HF ClinicalTrials.gov number, NCT01035255.).

References

YearCitations

1999

9K

1991

8K

1999

5.1K

1987

5.1K

1999

4.9K

2001

3.1K

2001

3.1K

2010

3K

2000

2.9K

2000

1.8K

Page 1